Willingdon Wealth Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Willingdon Wealth Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-336	Closed	-$18K	–	389
2018 Q4	$18K	Hold	336	–	–	0.01%	243
2018 Q3	$22K	Hold	336	–	–	0.01%	257
2018 Q2	$20K	Hold	336	–	–	0.01%	236
2018 Q1	$19K	Hold	336	–	–	0.01%	222
2017 Q4	$20K	Hold	336	–	–	0.01%	199
2017 Q3	$19K	Buy	+336	New	+$19.1K	0.01%	193

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Willingdon Wealth Management's PPH Position: Q1 2019 in Review

Willingdon Wealth Management sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2019, closing a stake of 336 shares — an estimated $18K sold.

Willingdon Wealth Management first reported a position in PPH in Q3 2017 and held it in 6 quarters. The position peaked at $22K in Q3 2018. 46 funds tracked by Wall St. Rank hold PPH as of Q1 2019.

Willingdon Wealth Management reported no remaining VanEck Pharmaceutical ETF position as of Q1 2019 after selling out during the quarter.
Willingdon Wealth Management sold 336 VanEck Pharmaceutical ETF shares in Q1 2019, an estimated $18K.
Willingdon Wealth Management first reported a position in VanEck Pharmaceutical ETF in Q3 2017 and held it in 6 quarters.
Willingdon Wealth Management's VanEck Pharmaceutical ETF position peaked at $22K in Q3 2018.
46 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2019.

Based on Willingdon Wealth Management's 13F filing for Q1 2019, filed 9 May 2019.